112 results
PRE 14A
SYRS
Syros Pharmaceuticals Inc.
12 Apr 24
Preliminary proxy
4:30pm
of directors with respect to fiscal 2023 included:
drug safety, including the safety of clinical trial participants;
manufacturing and supply chain
8-K
EX-99.1
SYRS
Syros Pharmaceuticals Inc.
8 Jan 24
Regulation FD Disclosure
7:06am
and future clinical trials the requisite safety, efficacy and combinability of its drug candidates; sustain the response rates and durability of response … demonstrated a well-tolerated safety profile 1Amnolake® post-marketing surveillance data on file; 2Data presented at ASH 2017; 3de Botton S., et al
8-K
EX-99.2
vx3qc1s5m09w
8 Jan 24
Regulation FD Disclosure
7:06am
8-K
EX-1.1
n95svw4qu
19 Dec 23
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
4:59pm
424B5
18cw4zibir8lub2p8s4
19 Dec 23
Prospectus supplement for primary offering
4:53pm
8-K
EX-99.1
6jcsbphdttrls2t2g624
6 Dec 23
Regulation FD Disclosure
7:05am
8-K
EX-99.2
94ftb 38m2
6 Dec 23
Regulation FD Disclosure
7:05am
8-K
EX-99.1
kne thohxu
25 May 23
Regulation FD Disclosure
5:10pm
8-K
EX-99.2
tld0559vl4310625s3
25 May 23
Regulation FD Disclosure
5:10pm
8-K
EX-99.2
rot86c
12 Dec 22
Regulation FD Disclosure
7:48am
8-K
e7gc8
12 Dec 22
Regulation FD Disclosure
7:48am
8-K
EX-99.1
9x9j4254
12 Dec 22
Regulation FD Disclosure
7:48am